Korean J Anesthesiol.  2013 Dec;65(6):495-500. 10.4097/kjae.2013.65.6.495.

Sugammadex: clinical development and practical use

• Fuchs-Buder T
• Meistelman C
• Raft J

• KMID: 2092374
• DOI: http://doi.org/10.4097/kjae.2013.65.6.495

Abstract

Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However it only works for reversal of rocuronium or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine.

Keyword

Cyclodextrins; Neostigmine; Neuromuscular block; Residual neuromuscular blockade; Rocuronium; Sugammadex

MeSH Terms

Cholinesterase Inhibitors
Cyclodextrins
Neostigmine
Neuromuscular Blockade
Neuromuscular Depolarizing Agents
Paralysis
Succinylcholine
Cholinesterase Inhibitors
Cyclodextrins
Neostigmine
Neuromuscular Depolarizing Agents
Succinylcholine